LEI 549300OLOH8YMZM9O838

JANSSEN PHARMACEUTICA

Group parent: Johnson & JohnsonJNJ · UN

Awards tracked

107

Value (latest 100)

€14.24M

Countries

BE

Download sample CSV

Contract awards & public grants

Improving Drug Efficacy with next-generation AmorphouS materials and trained experts → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2026-06-25

€288,540

FORTIFY - FRAMEWORK FOR OPTIMIZED REGULATION, TRADE SECRETS, AND INTELLECTUAL PROPERTY IN A FEDERATED EUROPEAN HEALTH DATA SPACE → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2026-06-02

—

MedTechLabel: UNIFIED DIGITAL LABELLING FOR MEDICAL TECHNOLOGY PRODUCTS → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2026-05-05

—

Towards predictive computational platform for drug solubilization in the gastrointestinal tract → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2026-03-11

—

Breakthrough Regulatory Innovation and Development throuGh sandbox Environments → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2025-11-07

—

101219311 - BRIDGE - BREAKTHROUGH REGULATORY INNOVATION AND DEVELOPMENT THROUGH SANDBOX ENVIRONMENTS → JANSSEN PHARMACEUTICA NV

IMI - Innov.Health Initiative · BE · Grant · 2025-11-01

€5.2M

Ultrahigh-throughput exploration of metagenomic sequence space to discover and engineer novel biocatalysts and bioactive compounds → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2025-07-08

€288,540

Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT) → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-12-16

—

Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-12-12

—

IMAGING FOR PATIENT BENEFIT IN ARTHRITIS → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-12-10

—

REpresentative Clinical Research - ADvancing Inclusivity in Europe → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-12-05

—

Advancing Safe and Sustainable by design Practices in Pharmaceutical Manufacturing → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-12-05

—

Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applications → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-08-09

—

Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-07-26

—

Crystallisation towards efficient and sustainable biomanufacturing → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2024-07-10

€262,620

Developing broad-spectrum antiviral drugs for pandemic preparedness → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2023-12-11

€80,432

Ion Mobility Mass Spectrometry Training Network → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2023-07-12

—

Base metal-catalytic cross-coupling methodologies towards sustainability → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2023-06-29

€262,620

IMAGING AND ADVANCED GUIDANCE FOR WORKFLOW OPTIMIZATION IN INTERVENTIONAL ONCOLOGY → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2023-05-15

—

Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2023-05-10

—

Clinical Trials Community Africa Network → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2023-05-02

—

Doctoral network for microprocess engineering for electrosynthesis - new synthesis concepts for pharmaceutical/ fine chemical industry → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2022-11-28

€262,620

How to minimize the ecological footprint for functional electronics? → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2022-06-15

€216,799

DIgital health in Circular Economy → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2022-06-07

€1.28M

CREATING FRAMEWORK CONDITIONS FOR RESEARCH MANAGEMENT TO STRENGTHEN THE EUROPEAN RESEARCH AREA → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2022-05-20

—

Oral delivery of encapsulated RNA nanotherapeutics for targeted treatment of ileal Crohn's disease → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2022-05-19

€299,202

European platform for neurodegenerative disorders → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2021-10-25

—

BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2021-09-27

—

ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2021-06-29

—

Allostery in Drug Discovery → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2021-05-28

€256,320

Preparing for RSV Immunisation and Surveillance in Europe → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2021-05-21

—

Using real-world big data from eHealth, biobanks and national registries, integrated with clinical trial data to improve outcome of severe mental diso → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2021-01-29

€502,169

Central Repository for Digital Pathology → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-11-26

—

Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-11-24

—

Gravitate–Health: Empowering and Equipping Europeans with health information for Active Personal Health Management and Adherence to Treatment → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-11-12

—

Accelerating Research & Development for Advanced Therapies → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-11-11

—

A fully integrated, animal-free, end-to-end modelling approach to oral drug product development → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-09-07

€384,480

Advanced machine learning for Innovative Drug Discovery → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-08-24

€640,800

Boosting advanced doctoral training in innovative colon targeting drugs → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-08-19

€256,320

Corona Accelerated R&D in Europe → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-08-07

—

Drug repurposing and discovery multidisciplinary training network → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-07-16

€256,320

Prioritisation and Risk Evaluation of Medicines in the EnviRonment → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-06-24

—

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-05-26

—

Process Analytical Technology Tools for Real-Time Physical and Chemical Characterization of Nanosuspensions → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-04-28

€255,250

Swift COronavirus therapeutics REsponse → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2020-04-08

—

Identifying Digital Endpoints to Assess FAtigue, Sleep and acTivities in daily living in Neurodegenerative disorders and Immune-mediated inflammatory → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-12-18

—

PharmaLedger → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-12-16

—

EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-12-12

—

EU Patient- cEntric clinicAl tRial pLatform → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-11-27

—

Collaboration for Prevention and Treatment of MDR Bacterial Infections → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-11-27

—

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-09-26

—

Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-08-22

—

Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-08-07

—

Long Acting Medicines for Complex Therapeutics Needed Now → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-07-25

€512,640

MachinE Learning Ledger Orchestration for Drug DiscoverY → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-05-22

—

A Centre of Excellence in Computational Biomedicine → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-05-13

€169,000

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-05-08

—

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytoc → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-05-08

—

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed w → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-05-06

—

Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-04-23

—

Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diag → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-04-08

—

The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-03-25

—

Efficiently Networking European Neurodegeneration Research → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-02-28

—

EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2019-02-28

—

FAIRplus → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-12-18

—

European Screening Centre; Unique Library for Attractive Biology → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-12-18

—

Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics (IM2PACT) Into The Brain → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-12-14

—

Remote Assessment of Disease and Relapse – Alzheimer’s Disease → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-12-05

—

European Health Data and Evidence Network → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-11-22

—

Artificial Intelligence to transform Drug and Chemical safety testing → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-10-03

€134,531

Multiscale Analysis of Thermomechanical Behaviour of Granular Materials → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-08-30

—

Autism Innovative Medicine Studies – 2 – Trials → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-06-22

—

conect4children (COllaborative Network for European Clinical Trials For Children) → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-06-22

—

Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-06-14

—

Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medici → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2018-06-04

—

Enhacing TRANslational SAFEty Assessment through Integrative Knowledge Management → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-09-12

—

Personalised In-Silico Cardiology → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-08-31

—

Memory research: Ground-breaking, Applied, and Technological Exchanges → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-08-31

€250,560

Rheuma Tolerance for Cure → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-08-25

—

European Quality In Preclinical Data → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-08-18

—

Interdisciplinary training network on the purinergic P2X7 receptor to control neuroinflammation and hyperexcitability in brain diseases. → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-08-17

—

ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-05-18

—

Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases - Sofia ref.: 116060 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-04-07

—

Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2017-01-30

—

Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-12-22

—

Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-12-22

—

Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-12-21

—

Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-12-16

—

REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-12-14

—

A global alliance for Zika virus control and prevention → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-12-13

€55,089

Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development - Sofia ref.: 115975 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-11-09

—

Solid Catalysts for activation of aromatic C-H bonds → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-11-09

€1.02M

Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-11-08

—

Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-10-21

—

Mechanisms and regulation of inflammasome-associated programmed cell death → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-06-22

€729,100

Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881 → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-06-07

—

A Centre of Excellence in Computational Biomedicine → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-06-03

€125,025

Remote Assessment of Disease and Relapse in Central Nervous System Disorders → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-03-31

—

Scientific Top Training in Antimicrobial Research → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-03-29

—

Pharmaceutical Education And Research with Regulatory Links: Innovative drug development strategies and regulatory tools tailored to facilitate earlie → JANSSEN PHARMACEUTICA NV

European Commission · BE · Grant · 2016-02-12

€250,560

Showing the latest 100 of 107 awards. Full feed via API or CSV

Entity identity is matched from published recipient names and registry IDs to GLEIF legal-entity records; matches can be imperfect. Source records are public procurement and grant notices.